1
Asano Osamu, Harada Hitoshi, Yoshikawa Seiji, Watanabe Nobuhisa, Inoue Takashi, Horizoe Tatsuo, Yasuda Nobuyuki, Ohashi Kaya, Minami Hiroe, Nagaoka Junsaku, Murakami Manabu, Kobayashi Seiichi, Tanaka Isao, Kawata Tsutomu, Shimomura Naoyuki, Akamatsu Hiroshi, Ozeki Naoki, Shimizu Toshikazu, Hayashi Kenji, Haga Toyokazu: Fused imidazole compounds and remedies for diabetes mellitus. Eisai, July 10, 2002: EP1221444-A1 (32 worldwide citation)

The present invention provides a preventive or therapeutic agent for diabetes mellitus and diabetic complications, which is a new type based on an adenosine A2 receptor antagonist action. That is, it provides a novel condensed imidazole compound which has an adenosine A2 receptor antagonist action, ...


2

3
Shinoda Masanobu, Matsuura Fumiyoshi, Murata Kaoru, Gotoda Masaharu, Hayashi Kenji, Sasho Manabu, Ozeki Naoki, Inoue Susumu, Nishiura Katsutoshi, Hisatake Yoshihiko, Takigawa Teiji, Miyazawa Mamoru, Negi Shigeto, Matsuyama Keisuke: Calcium bis [ (2s) - 3- [3-[ (2s) -3- (4-chloro-2-cyanophenoxy) -2- fluoropropoxy]phenyl ]-2-isopropoxypropionate] and intermediate thereof. Eisai, linbai nan liujin hui, April 16, 2008: CN200680013223

The present invention relates to calcium bis[(2 S )-3-[3-[(2 S )-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionate] represented by formula (I), a hydrate thereof, a crystal of the compound of formula (I), and a crystal of the hydrate of the compound of formula (I) which are ...


4
Harada Hitoshi, Ishihara Hiroshi, Sato Yoshiaki, Chiba Hiroyuki, Komatsu Yuki, Inoue Susumu, Ozeki Naoki: Pyrimidine compound crystal or amorphous form and process for producing the same. Eisai R &Amp D Man, yanghong jun, January 9, 2008: CN200680001972

Crystal of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1- methylpyridin-2(1H)-one exhibiting, in powder X-ray diffractometry, diffraction peaks at diffraction angles (2+-0.2 DEG ) of 12.8 DEG , 18.1 DEG and/or 23.5 DEG . This crystal excels in photostability, thereby being suitable for use as an active in ...


5
ASANO OSAMU, HARADA HITOSHI, YOSHIKAWA SEIJI, WATANABE NOBUHISA, INOUE TAKASHI, HORIZOE TATSUO, YASUDA NOBUYUKI, OHASHI KAYA, MINAMI HIROE, NAGAOKA JUNSAKU, MURAKAMI MANABU, KOBAYASHI SEIICHI, TANAKA ISAO, KAWATA TSUTOMU, SHIMOMURA NAOYUKI, AKAMATSU HIROSHI, OZEKI NAOKI, SHIMIZU TOSHIKAZU, HAYASHI KENJI, HAGA TOYOKAZU, NEGI SHIGETO, NAITO TOSHIHIKO: COMPOSES IMIDAZOLE FUSIONNES ET MEDICAMENTS CONTRE LE DIABETE SUCRE, CONDENSED IMIDAZOLE COMPOUNDS AND A THERAPEUTIC AGENT FOR DIABETES MELLITUS. EISAI, EISAI R&D MANAGEMENT, SMART & BIGGAR, September 15, 2009: CA2376835

The present invention provides a preventive or therapeutic agent for diabetes mellitus and diabetic complications, which is a new type based on an adenosine A2 receptor antagonist action. That is, it provides a novel condensed imidazole compound which has an adenosine A2 receptor antagonist action, ...


6
Shinoda Masanobu, Matsuura Fumiyoshi, Murata Kaoru, Gotoda Masaharu, Hayashi Kenji, Sasho Manabu, Ozeki Naoki, Inoue Susumu, Nishiura Katsutoshi, Hisatake Yoshihiko, Takigawa Teiji, Miyazawa Mamoru, Negi Shigeto, Matsuyama Keisuke: Calcium bis[2s)-3-[3-(2s)-3-(4-chloro-2-cyanophenoxy)-2- fluoropropoxy¨phenyl]-2-isopropoxypropionate] and intermediate thereof. Eisai R &Amp, D Man, January 2, 2008: EP1873141-A1

The present invention relates to calcium bis[(2 S )-3-[3-[(2 S )-3-(4-chloro-2-cyanophenoxy)-2-fluoropropoxy]phenyl]-2-isopropoxypropionate] represented by formula (I), a hydrate thereof, a crystal of the compound of formula (I), and a crystal of the hydrate of the compound of formula (I) which are ...


7
Harada Hitoshi, Ishihara Hiroshi, Sato Yoshiaki, Chiba Hiroyuki, Komatsu Yuki, Inoue Susumu, Ozeki Naoki: Pyrimidine compound crystal or amorphous form and process for producing the same. Eisai R & D Man, December 5, 2007: EP1862463-A1

Crystals of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1-methylpyridin-2(1 H )-one having a diffraction peak at a diffraction angle (2 +- 0.2 DEG ) of 9.7 DEG and/or 21.9 DEG in a powder X-ray diffraction are suitable for an active ingredient of a preventing and therapeutic agent for diseases such as con ...


8

9
Hayashi Kenji, Abe Taichi, Ozeki Naoki, Akamatsu Hiroshi: (Ja) スルホンアミド含有インドール化合物の製造方法, (En) Method for producing sulfone amide-containing indole compound. Eisai, Hayashi Kenji, Abe Taichi, Ozeki Naoki, Akamatsu Hiroshi, HASEGAWA Yoshiki, March 24, 2005: WO/2005/026119

(EN) Disclosed is a method for producing a compound (5a) represented by the following formula: (5a) (wherein A, R1 and R2 are as defined below) which is characterized by reacting a compound (3a) represented by the following formula: (3a) (wherein R1 and R2 independently represent a hydrogen atom, a ...


10
Harada Hitoshi, Ishihara Hiroshi, Sato Yoshiaki, Chiba Hiroyuki, Komatsu Yuki, Inoue Susumu, Ozeki Naoki: (Ja) ピリミジン化合物の結晶、非晶質および製造方法, (En) Pyrimidine compound crystal or amorphous form and process for producing the same. Eisai R & D Management, Harada Hitoshi, Ishihara Hiroshi, Sato Yoshiaki, Chiba Hiroyuki, Komatsu Yuki, Inoue Susumu, Ozeki Naoki, HASEGAWA Yoshiki, September 28, 2006: WO/2006/101082

(EN) Crystal of 5-[2-amino-4-(2-furyl)pyrimidin-5-yl]-1- methylpyridin-2(1H)-one exhibiting, in powder X-ray diffractometry, diffraction peaks at diffraction angles (2&thetas;±0.2°) of 9.7° and/or 21.9°. This crystal is suitable for use as an active ingredient of preventive/therapeutic agents for di ...